Apolipoprotein E1-Hammersmith (Lys146 → Asn;Arg147 → Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia

Atherosclerosis

Volumn 124, Issue 2, 1996, Pages 183-189

  Hoffer, Mariëtte J V ^a   Niththyananthan, Sarojinidevi ^b   Naoumova, Rossitza P ^b   Kibirige, Mohammed S ^c   Frants, Rune R ^a   Havekes, Louis M ^d   Thompson, Gilbert R ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d TNO   (Netherlands)

Author keywords

Apolipoprotein E; Dyslipidaemia; Fenofibrate; Point mutation

Indexed keywords

APOLIPOPROTEIN E; CLOFIBRATE; COLESTYRAMINE; FENOFIBRATE; MERCAPTAMINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; POINT MUTATION; PRIORITY JOURNAL;

EID: 0030565015     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05819-4     Document Type: Article

References (30)

1. [1] Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipid metabolism. In: Scriver C, Beaudet AL, Sly WS and Valle D. (eds). The Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw Hill, 1989;1195.
2. [2] Sherill BC, Innerarity Tl, Mahley RW. Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. J Biol Chem 1980;255:1804.
3. [3] Mahley RW, Innerarity TL, Rall SC Jr. Weisgraber KH, Taylor JM, Apolipoprotein: genetic variants provide insights into its structure and function. Curr Opin Lipidol 1990;1:87.
4. [4] De Knijff P, van den Maagdenberg AMJM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mut 1994;4:178.
5. [5] Utermann G, Hees M. Steinmez A. Polymorphism of apolipoprotein E and occurence of dysbetalipoproteinemia in man. Nature 1977;269:604.
6. [6] Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW, Assmann G. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo- and hypercholesterolemic dysbetalipoproteinemia. J Clin Invest 1983;71:1023.
7. [7] Thompson GR. A handbook of hyperlipidaemia, revised ed., Current Science Ltd., London, 1994.
8. [8] McDowell IFW, Wisdom GB and Trimble ER. Apolipoprotein E phenotyping determined by agarose gel electrofocusing and immunoblotting. Clin Chem 1989;35:2070.
9. [9] Havekes LM, De Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987;28:455.
10. [10] Miller SAD, Dykes D, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
11. [11] De Knijff P, van den Maagdenberg AMJM, Stalenhoef AFH, Gevers Leuven JA, Demacker PNM, Kuyt LP, Frants RR, Havekes LM. Familial dysbetalipoproteinaemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991;88:643.
12. [12] Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31:545.
13. [13] Van den Maagdenberg AMJM, Weng W, de Bruijn IH, de Knijff P, Funke H, Smelt AHM, Gevers Leuven JA, van't Hooft FM, Assman G, Hofker MH, Havekes LM, Frants RR. Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no co-segregation with severe hyperlipidemia. Am J Hum Genet 1993;52:937.
14. [14] Tamir I, Heiss G, Glueck CJ, Christensen B, Kwiterovich P, Rifkind BM. Lipid and lipoprotein distributions in white children ages 6-19 yr. The Lipid Research Clinics Program Prevelance Study. J Chron Dis 1981;34:27.
15. [15] Paik Y-K, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA 1985;82:3445.
16. [16] Cummings MH, Watts GF, Pal C, Umpleby M, Hennessy TR, Naoumova R, Sönksoen PH. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin Sci 1995;88:225.
17. [17] Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJP, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 1981;78:2591.
18. [18] Rall SC, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA 1982;79:1075.
19. [19] Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW. Familial dysbetalipoproteinemia. Abnormal binding of mutant apolipoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenals of rats, rabbits and cows. J Clin Invest 1981;68:1075.
20. [20] Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science 1981;211:584.
21. [21] Mann WA, Gregg RE, Sprecher DL, Brewer HB Jr. Apolipoprotein E-1-Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim Biophys Acta 1989;1005:239.
22. [22] Rall SC, Weisgraber KH, Innerarity TL, Bersot TP, Mahley RW. Identification of a new structural variant of human apolipoprotein E, E2(Lysl46→Gln) in a type III hyperlipoproteinemic subject with E3/E2 phenotype. J Clin Invest 1983;72:1288.
23. [23] Smit M, De Knijff P, van der Kooij-Meijs E, Groenendijk C. van den Maagdenberg AMJM, Gevers Leuven JA, Stalenhoef AFH, Stuyt PMJ, Frants RR, Havekes LM. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(Lysl46→Gln) variant results in a dominant mode of inheritance. J Lipid Res 1990;31:45.
24. [24] de Knijff P, van den Maagdenberg AMJM, Boomsma DI, Stalenhoef AFH, Smelt AHM, Kastelein JJP, Marais AD, Frants RR, Havekes LM. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2(Lysl46→ Gln) allele carriers. J Clin Invest 1994;94:1252.
25. [25] Weisgraber KH, Rall SC Jr, Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 1986;261:2068.
26. [26] Westerlund JA, Weisgraber KH. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem 1993;268:15745.
27. [27] Mulder M, Van der Boom H, De Knijff P. Braam C, Van den Maagdenberg A, Gevers-Leuven JA, Havekes LM. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lysl46→Gln) are inefficiently converted to cholesterol-rich lipoproteins. Atherosclerosis 1994;108:183.
28. [28] Mann WA, Lohse P, Gregg RE, Ronan R, Hoeg JM, Zech LA, Brewer HB Jr. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of apoEl(Lysl46→Glu). J Clin Invest 1995;96:1100.
29. [29] Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991;252:1817.
30. [30] Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249.